Evidence map›Paper›PMID 18814834›Full record

ArticleCurrent treatment options in cardiovascular medicine2008

Ventricular arrhythmia in children: diagnosis and management.

Gerald Serwer

Abstract read
PubMed Publisher
In one paragraph

Article in Current treatment options in cardiovascular medicine, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Gerald SerwerUniversity of Michigan Congenital Heart Center, Department of Pediatrics, University of Michigan Health System, Box 5204, 1500 East Medical Center Drive, Ann Arbor, MI 48109, USA. gserwer@umich.edu

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With increasing awareness of genetic abnormalities and the aging of patients with structural cardiac disease, particularly those who have had cardiac surgery, primary ventricular tachycardia is being recognized more frequently in children and adolescents and is becoming a larger management issue. The distinction of primary versus secondary is based on whether ventricular tachycardia is the inciting arrhythmia or the end result of a prolonged ischemic event, such as prolonged bradycardia with resultant ventricular tachycardia. This article discusses only primary ventricular tachycardia. The incidence clearly increases with age after cardiac surgery, particularly in specific cardiac abnormalities, such as tetralogy of Fallot post repair, transposition of the great arteries, post atrial switch operation, and hypertrophic obstructive cardiomyopathy. In addition, as genetic abnormalities are becoming better appreciated, conditions such as long QT syndrome, arrhythmogenic right ventricular cardiomyopathy, and Brugada syndrome, with their risk for ventricular tachycardia and fibrillation, are being seen increasingly in the pediatric population. Long-term treatment of ventricular tachycardia includes drug therapy, implantable device therapy, invasive ablation therapy, and combinations of these modalities. To choose the appropriate therapy, the clinician must consider the arrhythmia's effect on the patient's hemodynamic status and the potential for sudden cardiac death.

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.